L Kappos Selected Research

L Kappos Research Topics

Disease

62	Multiple Sclerosis 01/2020 - 01/2000
16	Relapsing-Remitting Multiple Sclerosis 01/2020 - 10/2000
8	Chronic Progressive Multiple Sclerosis 01/2022 - 11/2000
5	Inflammation (Inflammations) 04/2011 - 02/2001
4	Progressive Multifocal Leukoencephalopathy 12/2011 - 09/2008
4	Atrophy 10/2010 - 11/2000
4	Disease Progression 04/2005 - 09/2001
3	Infections 04/2014 - 02/2010
3	Opportunistic Infections (Opportunistic Infection) 05/2011 - 04/2000
3	Autoimmune Diseases (Autoimmune Disease) 03/2005 - 05/2000
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2014 - 12/2000
2	Immune Reconstitution Inflammatory Syndrome 12/2011 - 05/2011
2	Ischemic Stroke 04/2011 - 02/2011
2	Bacterial Meningitis 06/2006 - 10/2001
2	Lymphoma (Lymphomas) 10/2000 - 04/2000
1	Pathologic Nystagmus 10/2016
1	Paresis (Hemiparesis) 12/2011
1	Fatigue 11/2011
1	Stroke (Strokes) 04/2011
1	Transient Ischemic Attack 02/2011
1	Skin Neoplasms (Skin Cancer) 02/2010
1	Injection Site Reaction 10/2009
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 06/2009
1	Hypersensitivity (Allergy) 11/2006
1	Meningitis 06/2006
1	Leukocytosis (Pleocytosis) 06/2006
1	Edema (Dropsy) 01/2005
1	Demyelinating Diseases (Demyelinating Disease) 09/2001
1	Necrosis 09/2001

Drug/Important Bio-Agent (IBA)

12	Fingolimod Hydrochloride (FTY720)FDA Link 01/2020 - 10/2008
12	Interferon beta-1b (Betaseron)FDA Link 04/2016 - 11/2000
9	Natalizumab (Tysabri)FDA Link 10/2018 - 11/2006
8	Interferon beta-1a FDA Link 03/2011 - 11/2002
7	InterferonsIBA 10/2017 - 09/2006
5	GadoliniumIBA 10/2017 - 11/2005
5	Glatiramer Acetate (Copaxone)FDA Link 01/2015 - 12/2000
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2011
4	Matrix Metalloproteinases (MMPs)IBA 06/2006 - 02/2001
3	AntibodiesIBA 08/2016 - 08/2003
3	Neutralizing AntibodiesIBA 08/2011 - 01/2003
3	Sphingosine-1-Phosphate ReceptorsIBA 02/2011 - 01/2009
3	Interferon-betaIBA 03/2005 - 08/2003
2	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2019 - 01/2005
2	ocrelizumabIBA 01/2019 - 08/2016
2	Dimethyl FumarateIBA 05/2017 - 04/2015
2	teriflunomideIBA 01/2015 - 06/2012
2	N-acetylaspartate (N-acetyl aspartate)IBA 01/2012 - 08/2000
2	Biological ProductsIBA 07/2011 - 08/2009
2	Hormones (Hormone)IBA 04/2011 - 02/2011
2	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 02/2011 - 08/2010
2	EnzymesIBA 06/2006 - 04/2005
2	CytokinesIBA 11/2005 - 09/2001
1	mono(2-methacryloyloxy)ethyl phthalate (MMEP)IBA 01/2022
1	Dihydrotachysterol (AT 10)IBA 01/2020
1	LithiumIBA 10/2016
1	Rituximab (Mabthera)FDA Link 08/2016
1	Alemtuzumab (Campath)FDA Link 08/2016
1	Therapeutic UsesIBA 05/2014
1	Angiotensin Receptor AntagonistsIBA 01/2014
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2014
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2014
1	DNA (Deoxyribonucleic Acid)IBA 12/2011
1	HLA-G Antigens (HLA G)IBA 08/2011
1	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2011
1	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 04/2011
1	Hydrocortisone (Cortisol)FDA LinkGeneric 04/2011
1	Thyroxine (Levothyroxine)FDA LinkGeneric 04/2011
1	Growth Hormone (Somatotropin)IBA 04/2011
1	Triiodothyronine (Liothyronine)FDA LinkGeneric 04/2011
1	Thyroid HormonesIBA 04/2011
1	AntigensIBA 02/2011
1	Neuroprotective AgentsIBA 10/2010
1	Biosimilar PharmaceuticalsIBA 08/2009
1	Generic DrugsIBA 08/2009
1	ChemokinesIBA 06/2009
1	Protective AgentsIBA 05/2009
1	Immunologic Factors (Immunomodulators)IBA 10/2008
1	Retinaldehyde (Retinal)IBA 05/2008
1	Proteins (Proteins, Gene)FDA Link 06/2006
1	GelatinasesIBA 06/2006
1	Collagenases (Collagenase)FDA Link 06/2006
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 06/2006
1	Bromelains (Bromelain)IBA 04/2005
1	TrypsinIBA 04/2005
1	Pharmaceutical PreparationsIBA 03/2005
1	AutoantibodiesIBA 03/2005
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2001
1	A-factor (Streptomyces)IBA 09/2001
1	ADAM17 ProteinIBA 09/2001
1	Messenger RNA (mRNA)IBA 09/2001
1	Metalloproteases (Metalloproteinases)IBA 09/2001

Therapy/Procedure

18	Therapeutics 01/2020 - 01/2000
3	Aftercare (After-Treatment) 05/2011 - 06/2000
2	Transplantation 08/2002 - 05/2000
1	Injections 05/2014
1	Duration of Therapy 05/2014
1	Plasmapheresis 12/2011
1	Oral Administration 04/2005
1	Immunotherapy 11/2004
1	Hematopoietic Stem Cell Transplantation 08/2002